Galapagos NV American Depositary Receipt (GLPG)
NASDAQ (NGS) 
Summary
GLPG Chart
Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript
Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript
Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation
Galapagos now presents a deep value opportunity, underpinned by a €3B cash reserve and a decisive shift to capital allocation discipline. GLPG's restructuring—discontinuing cell therapy, slashing headcount, and targeting cash flow neutrality by YE2026—positions it as a streamlined M&A platform. Management's M&A-focused pedigree, led by ex-AbbVie dealmakers, signals a pivot from pipeline reliance to transformative business development using its cash war chest.
Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101
Galapagos NV released positive data from the phase 1/2 ATALANTA-1 study using GLPG5101 for the treatment of patients with relapsed/refractory Mantle Cell Lymphoma; 100% ORR/CR was achieved in 8 patients. Updated data from the relapsed/refractory Mantle Cell Lymphoma cohort from the phase 1/2 ATALANTA-1 study is to be presented at a medical conference presentation 2nd half of 2025. The global MCL market is expected to reach $5.77 billion by the end of 2034; Between 15% to 20% of MCL patients who receive front-line therapy progress within 2 years.
Galapagos NV American Depositary Receipt Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ADD Andrew D. Dickinson GILEAD SCIENCES Inc. | 16.71M | $461.73M | $461.73M | - | - |
 David Einhorn Greenlight Capital Re Ltd. | 162,578 | $8.65M | $8.96M | $313,999.42 | 3.63% |
 Point72 Asset Management LP Point72 Asset Management LP | 332,125 | $10.18M | $9.3M | -$880,175.18 | -8.65% |
 Madison Avenue Partners LP Madison Avenue Partners LP | 2.47M | $71.71M | $69M | -$2.71M | -3.78% |
 Li Peng China Universal Asset Management Co. Ltd. | 2,631 | $78.7 | $78.93 | $0.23 | 0.29% |
Galapagos NV American Depositary Receipt (GLPG) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Galapagos NV American Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Henry Gosebruch CEO | NASDAQ (NGS) Exchange | 36315X101 CUSIP |
| BE Country | 704 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Galapagos NV is a leading biotechnology firm dedicated to discovering and developing innovative medicines, with a focus on oncology and immunology. With its primary operations in the United States and Europe, Galapagos NV has established a significant presence in the biopharmaceutical industry through its commitment to addressing unmet medical needs. The company has formed strategic alliance agreements with major players like Gilead Sciences, Inc. and AbbVie S.à r.l., enhancing its research capabilities and market reach. Founded in 1999 and headquartered in Mechelen, Belgium, Galapagos NV continues to forge ahead in the biotechnology field, underpinned by a robust pipeline of potential breakthrough therapies.
Products and Services
- GLPG3667 - This is a promising candidate that has successfully completed phase 1b trial. The focus of GLPG3667 is on demonstrating safety and efficacy for potential use in treating specific conditions, though the exact therapeutic area is not specified, showing the company's commitment to expanding its portfolio.
- GLPG5101 - A cutting-edge CD19 CAR-T product candidate that is currently under Phase 1/2 trial for relapsed/refractory non-Hodgkin lymphoma. This therapy represents the advancement in cellular immunotherapy, targeting CD19, a protein commonly found on the surface of B cells and involved in many B cell malignancies. What makes GLPG5101 stand out is its point-of-care manufacturing process, which could revolutionize the accessibility and effectiveness of CAR-T therapies.
- GLPG5201 - Similar to GLPG5101, GLPG5201 is also a CD19 CAR-T product candidate but specifically focused on a different indication: relapsed/refractory chronic lymphocytic leukemia. Currently in phase 1/2 trial, GLPG5201 harnesses the same innovative point-of-care manufacturing technology, showing Galapagos' strategic approach to tackling various hematologic malignancies with targeted cellular therapies.
- GLPG5301 - Diversifying its CAR-T portfolio, Galapagos NV presents GLPG5301, a BCMA (B-cell maturation antigen) CAR-T product candidate. This therapeutic is in phase 1/2 trials for relapsed/refractory multiple myeloma, a type of cancer that affects plasma cells. As with its other CAR-T candidates, GLPG5301 is manufactured at the point-of-care, underscoring the company's dedication to developing advanced treatments for complex diseases.
